Pharma-Natural Recalls Double Tussin DM Due to Manufacturing Violations
Pharma-Natural Inc. is recalling 500 bottles of Double Tussin DM because the product was manufactured with current good manufacturing practice violations.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The source text explicitly identifies the recall as FDA Class II. According to the severity rubric, FDA Class II recalls are classified as Severe (Score 4).
Plain-English summary
Pharma-Natural Inc. is recalling 500 bottles of Double Tussin DM (Dextromethorphan Hbr 20 mg, Guaifenesin 300 mg) in 4 FL OZ (120 mL) bottles. The product is distributed by Pamby Dist. in Miami, FL, and carries NDC 63708-121-04. The recall covers all lots remaining within their expiry dates.
The recall was initiated due to current good manufacturing practice (CGMP) deviations. Specifically, the products were manufactured with a lack of process validation, cleaning validation, stability studies, and other CGMP violations. The agency has classified this recall as Class II.
The product was distributed to consignees in Florida and Texas, who may have further distributed it nationwide in the USA and Puerto Rico. Consumers should check their home medicine cabinets for this specific product and stop using it if found.
The recalled product
- Product
- DOUBLE TUSSIN DM (Dextromethorphan Hbr 20 mg, Guaifenesin 300 mg) in each 5ml teaspoon, 4 FL OZ (120 mL) bottle, Distributed by: Pamby Dist., Miami, FL 33414, NDC 63708-121-04.
- Manufacturer
- Pharma-Natural Inc.
- Category
- Drug — Cough and Cold
- Affected units
- 500
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots remaining within expiry.
Distribution
Part of a larger recall action
This product is one of 16 recalled by Pharma-Natural Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 16 products in this recall →Related recalls
Same manufacturer · Pharma-Natural Inc.
See all →- ModeratePharma Natural Biotin 5000 mcg Dietary Supplement Recalled for Sub-Potency
FDA (Food) · 2023-10-04
- ModeratePharma-Natural Recalls LidoAID Gel Due to Manufacturing Violations
FDA (Drugs) · 2019-07-31
- ModeratePharma-Natural Recalls AbeeMed Cream Due to Manufacturing Violations
FDA (Drugs) · 2019-07-31
- ModeratePharma-Natural Recalls SORBUGEN Cough Syrup Due to Manufacturing Violations
FDA (Drugs) · 2019-07-31
- ModerateLido E.R. Lidocaine Cream Recalled for Manufacturing Violations
FDA (Drugs) · 2019-07-31
Same hazard · cgmp violations
See all →- ModeratePharma-Natural Recalls Tusslin Cough Syrup Due to Manufacturing Violations
FDA (Drugs) · 2019-07-31
- ModeratePharma-Natural Recalls Dayma Pain Gel for Manufacturing Violations
FDA (Drugs) · 2019-07-31
Similar recalls
- HighGuaifenesin and dextromethorphan liquid medication recalled for manufacturing control issues
FDA (Drugs) · 2022-09-14
- ModerateHerbal Doctor Remedies Recalls Detensin Capsules Due to Manufacturing Deviations
FDA (Drugs) · 2019-08-14
- HighGuaifenesin and Dextromethorphan Cough Syrup Recalled for Manufacturing Control Deviations
FDA (Drugs) · 2022-09-14
- HighCough medicine recalled due to manufacturing process deviation with non-food lubricant
FDA (Drugs) · 2023-06-07
- ModerateCough Medicine Recall: Undeclared Alcohol in Wal-Tussin DM
FDA (Drugs) · 2022-05-04
- HighRamipril Capsule Medication Recalled Over Unapproved Vendor Manufacturing Deviations
FDA (Drugs) · 2024-11-27